CRCTU-led vaccine study open to immunocompromised teens

Brave little girl having blood collection for tests

For the first time, patients aged 12-17 years and immunocompromised are taking part in research to work out how they respond to COVID-19 vaccination.

The OCTAVE study, led from the Universities of Glasgow and Birmingham and run by Birmingham’s Cancer Research UK Clinical Trials Unit recruited adults across 10 sites in the UK from May 2021 and looked at the response to COVID19 vaccines in immunocompromised adults as part of the COVID-19 Immunity National Core Study.

Now, with funding from the Vaccine Task Force, doctors and research teams from across the UK have come together to answer key questions for their teenage immune-suppressed patients, as well as adults.

he study extension for 12-17 year olds is part-funded by the NIHR GOSH Biomedical Research Centre (BRC), the only UK BRC specialising in paediatric research.

Teenagers recruited into the study will have received the COVID-19 mRNA Vaccine BNT162b2 (Pfizer/BioNTech) in line with guidelines from the National COVID-19 vaccination programme.

“We encourage patients and families to come forward for vaccination when invited. This research could help us work out exactly how children and young people in ‘at-risk’ groups respond to COVID-19 vaccination, and should give important information on how often boosters may be needed in this vulnerable group,” said Dr Rossa Brugha, Lead consultant at GOSH for OCTAVE and Consultant in Paediatric Lung Transplantation.

The study will recruit up to 160 children between 12 and 17 years old who are already immunocompromised patients – including some children and young people with conditions like juvenile arthritis, who are receiving cancer treatments like chemotherapy or those who have received a new vital organ – like a heart, lung or kidney – and require immune-suppressants to limit organ rejection. The team expects to have its first set of results by Autumn 2022.

Professor Pam Kearns, Director of the University of Birmingham’s Cancer Research UK Clinical Trials Unit, which is co-ordinating OCTAVE, commented: “This extension study is a great step forward for the over 12s but we are hoping to also amend the study to also include five-12 year olds to capture the full age range of immunocompromised patients receiving the COVID vaccines. As soon as we are offering this vaccine at any age, we want to be robustly and accurately recording the data through a research programme, just as we have for adults.”